<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4521">
  <stage>Registered</stage>
  <submitdate>28/03/2014</submitdate>
  <approvaldate>28/03/2014</approvaldate>
  <nctid>NCT02137850</nctid>
  <trial_identification>
    <studytitle>Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Previously Untreated Patients With Haemophilia A</studytitle>
    <scientifictitle>An Open-label Single-arm Multicentre Non-controlled Phase 3a Trial Investigating Safety and Efficacy of N8-GP in Prophylaxis and Treatment of Bleeding Episodes in Previously Untreated Paediatric Patients With Severe Haemophilia A</scientifictitle>
    <utrn />
    <trialacronym>pathfinder™6</trialacronym>
    <secondaryid>2013-004025-88</secondaryid>
    <secondaryid>NN7088-3908</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Congenital Bleeding Disorder</healthcondition>
    <healthcondition>Haemophilia A</healthcondition>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Clotting disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Other human genetics and inherited disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - turoctocog alfa pegol

Experimental: 50 EDs (exposure days) - 


Treatment: drugs: turoctocog alfa pegol
For intravenous (i.v.) injection. Frequency and dosage (20-75 U/kg) dependent on whether given as treatment for bleeding episode or as prophylaxis

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Incidence of inhibitory antibodies against coagulation factor VIII (FVIII)</outcome>
      <timepoint>When the first 50 PUP have reached at least 50 exposure dates. (Expected to reach between 6 - 18 months)</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Incidence of inhibitory antibodies against coagulation factor VIII (FVIII)</outcome>
      <timepoint>When the first 100 PUP have reached 100 exposure dates. (Expected to reach between 12 - 24 months)</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Incidence of inhibitory antibodies against coagulation factor VIII (FVIII)</outcome>
      <timepoint>At the end of the trial. End of trial will be up to 4 years after the patient has reached 100 exposure dates. (Expected to reach between 12 - 60 months)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Frequency of adverse events including serious adverse events and medical events of special interest</outcome>
      <timepoint>When the first 50 PUP have reached at least 50 exposure dates, when the first 100 PUP have reached 100 exposure dates, and at end of trial. End of trial will be up to 4 years after the patient has reached 100 exposure dates</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of confirmed high titre inhibitors (defined as inhibitor titre above 5 Bethesda Units (BU)</outcome>
      <timepoint>When the first 50 PUP have reached at least 50 exposure dates, when the first 100 PUP have reached 100 exposure dates, and at end of trial. End of trial will be up to 4 years after the patient has reached 100 exposure dates</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of breakthrough bleeding episodes during prophylaxis with N8-GP (annualised bleeding rate)</outcome>
      <timepoint>When the first 50 PUP have reached at least 50 exposure dates, when the first 100 PUP have reached 100 exposure dates, and at end of trial. End of trial will be up to 4 years after the patient has reached 100 exposure dates</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Haemostatic effect of N8-GP in treatment of bleeding episodes, assessed by a predefined 4-point haemostatic response scale ("excellent", "good", "moderate" and "none")</outcome>
      <timepoint>When the first 50 PUP have reached at least 50 exposure dates, when the first 100 PUP have reached 100 exposure dates, and at end of trial. End of trial will be up to 4 years after the patient has reached 100 exposure dates</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Informed consent obtained before any trial-related activities. Trial-related
             activities are any procedures that are carried out as part of the trial, including
             activities to determine suitability for the trial

          -  Male, age below 6 years of age at the time of signing informed consent

          -  Diagnosis of severe haemophilia A (FVIII activity level 1%) based on medical records
             or central laboratory results

          -  No prior use of purified clotting factor products (5 previous exposures to blood
             components is acceptable)</inclusivecriteria>
    <inclusiveminage />
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>6</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Male</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Any history of FVIII inhibitor (defined by medical records)

          -  Known or suspected hypersensitivity to trial product or related products

          -  Previous participation in this trial. Participation is defined as first dose
             administered of trial product

          -  Receipt of any investigational medicinal product within 30 days before screening

          -  Congenital or acquired coagulation disorder other than haemophilia A

          -  Any chronic disorder or severe disease which, in the opinion of the Investigator,
             might jeopardise the patient's safety or compliance with the protocol

          -  Patient's parent(s')/legally acceptable representative (LAR(s')) mental incapacity,
             unwillingness to cooperate, or a language barrier precluding adequate understanding
             and cooperation</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>125</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/11/2021</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD</recruitmentstate>
    <hospital>Novo Nordisk Investigational Site - South Brisbane</hospital>
    <postcode>4101 - South Brisbane</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Idaho</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nebraska</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Klagenfurt</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Plovdiv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Mörfelden-Walldorf</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Athens</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Tel-Hashomer</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Shizuoka-shi, Shizuoka</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Kuala Lumpur</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Bucharest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Bangkok</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Novo Nordisk A/S</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This trial is conducted globally. The aim of the trial is to investigate the safety and
      efficacy of turoctocog alfa pegol (N8-GP) in previously untreated patients (PUPs) with
      haemophilia A.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02137850</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Global Clinical Registry (GCR, 1452)</name>
      <address>Novo Nordisk A/S</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>